Patent Expiry

Patent/Exclusivity Expiry: REVUFORJ

Other upcoming events for SNDX

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Inten
Patent ExpiryPatent/Exclusivity Expiry: VYXEOS

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: REVUFORJ — SNDX Patent Expiry | BioSniper